Historically, pharmacogenetic research has involved candidate gene studies focused largely on associations between common polymorphisms in drug-metabolizing enzymes (e.g., CYP2D6 and CYP2C19) and drug disposition (mostly), toxicity (sometimes), and/or efficacy (rarely). Enormous technological advances in sequencing and genotyping have ushered in a new era in human genetics and pharmacogenetics research. Genomewide genotyping and sequencing approaches are widely being used to discover variants in any gene that underlie various phenotypes. As a result, both common and rare variants in many genes, including membrane transporter genes, have been identified as major determinants of variation in drug disposition, response, and toxicity. In this State of the Art Review, we describe the current knowledge of genetic polymorphisms and their effects on drug response in two major superfamilies of transporters: the Solute Carrier Superfamily (SLC) and the ATP-Binding Cassette superfamily (ABC). In particular, we focus on transporters that have been recognized by the International Transporter Consortium (ITC) 1 and regulatory authorities as important determinants of drug disposition and drug-drug interactions (DDIs) (see Table 1 ). In a previous publication from the ITC, we highlighted associations between common polymorphisms in two transporters, BCRP (ABCG2) and OATP1B1 (SLCO1B1), and variation in therapeutic drug response, drug toxicity, or drug disposition, and recommended that polymorphisms in these two transporters be considered during drug development. 2 Since that review, studies have continued to be published demonstrating significant associations between various pharmacogenomics traits and polymorphisms in ABCG2 and SLCO1B1. In addition, a number of recent studies have demonstrated that genetic variants in the Organic Cation Transporter 1 (OCT1, SLC22A1) are associated with the disposition and/or effects of a number of prescription drugs. [3] [4] [5] It is now not uncommon for regulatory agencies to expect data regarding the pharmacogenetic impact of genetic variation in these transporters in relevant drug development programs. Therefore, this review summarizes associations between polymorphisms in ABCG2, SLCO1B1, and SLC22A1 and pharmacogenomic phenotypes, focusing on clinical evidence and implications ( Figure 1 ). In addition, associations between genetic variants in other transporters and clinical drug phenotypes are described with some emphasis on transporters that are known to mediate clinical DDIs ( Figure 1) . Notably, the review focuses on germline (heritable) variants, and does not include mutations that may arise in somatic cells such as tumors. Following our summaries of clinical associations of germline variants in transporters, we describe functional genomic studies of heritable transporter polymorphisms. The review ends with a description of recent discoveries in transporter polymorphisms, which have been made using genomewide association (GWA) and massively parallel sequencing approaches. Comments on the use of pharmacogenomics data to support modeling and simulation as well as future directions are included.
HIGHLY IMPORTANT TRANSPORTER POLYMORPHISMS IN ABCG2 (BCRP), SLCO1B1 (OATP1B1), AND SLC22A1 (OCT1)
In the previous ITC publication, polymorphisms in ABCG2 and SLCO1B1 were considered highly significant because they met the following strict criteria: 1) At least one genomewide significant association (P < 5310 -8 ) between a polymorphism in the transporter and a pharmacologic trait for one or more drugs. The trait could reflect drug disposition, therapeutic response or drug toxicity; 2) Significant associations in multiple candidate gene studies with pharmacologic traits; and 3) In vitro evidence that Table 1 List of URLs to the guidelines and guidance from the Food and Drug Administration (FDA), European Medical Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), and International Council for Harmonization (ICH), which are mentioned in this review the polymorphism(s) exhibited functionally important effects on transporter activity or expression levels. In this review, these criteria again support the selection of functionally significant polymorphisms in ABCG2 and SLCO1B1. In this updated publication, we considered transporters in which compelling evidence for an association with a drug response phenotype existed in multiple candidate gene studies (without GWA evidence). OCT1 (SLC22A1) represented a transporter that met this criterion. In particular, many candidate gene studies indicate an important role for polymorphisms in OCT1 as modulators of drug disposition and response ( Figure 1 ). In addition, although none of the SLC22A1 polymorphisms have been associated with a pharmacogenomics trait in GWAS, SLC22A1 polymorphisms have been associated with levels of endogenous metabolites, and other traits in several GWAS (see GWAS Catalog).
Highly important polymorphisms in ABCG2 and SLCO1B1
Since publication of the previous study, 2 new reports continue to validate associations between pharmacologic traits and polymorphisms in ABCG2 and SLCO1B1. To date, a total of eight GWAS have reported genomewide level significant associations (P < 5310 -8 ) between polymorphisms in ABCG2 and SLCO1B1 and drug disposition or response (Supplemental Table S1 ). Significant associations have been described for drugs used in the treatment of lipid disorders (statins), gout (allopurinol), cancer (methotrexate), and cardiovascular disorders (ticagrelor). Among the eight GWAS, four are related to drug disposition and four are related to therapeutic or adverse drug response. All of the drugs were known substrates of the transporters with the exception of allopurinol. Allopurinol was discovered to be a substrate of ABCG2, through functional studies motivated by GWAS findings. 6 Future studies are required to replicate the associations between SLCO1B1 genetic polymorphisms and the active ticagrelor metabolite, AR-C124910XX, and to determine whether the metabolite is also a substrate of OATP1B1. 7 In general, the nonsynonymous polymorphism in SLCO1B1 (rs4149056) which results in an amino acid substitution (Val174Ala) is of most interest, and has been either directly associated with the pharmacologic trait or is in linkage disequilibrium with another variant that has been associated with the trait (Table S1 ). For ABCG2, multiple polymorphisms have been associated with various traits, although typically the missense polymorphism rs2231142, resulting in a substitution of lysine for glutamine (Q141K), is in linkage disequilibrium with the associated polymorphisms (Table S1) . Collectively, the studies summarized in Table S1 continue to support the ITC recommendation that genetic polymorphisms in SLCO1B1 and ABCG2 should be monitored during drug development. It is worth mentioning that the Clinical Pharmacogenetics Implementation Consortium (CPIC) has included polymorphisms in SLCO1B1 and ABCG2 as important determinants of drug disposition and response (https://cpicpgx. org/genes-drugs/). Among the gene/drug pairs, CPIC has published extensive evidence from the literature to support simvastatin dosing based on SLCO1B1 genotype (https://cpicpgx.org/ guidelines/guideline-for-simvastatin-and-slco1b1/).
Highly important polymorphisms in SLC22A1
During the third workshop of the ITC, SLC22A1 was discussed as being increasingly important in drug development due to a high level of evidence from a number of clinical pharmacogenomic studies (Table S2) . In this issue, Zamek-Gliszczynski et al. and Chu et al. respectively highlight the importance of SLC22A1 as an emerging transporter and provide also information on endogenous biomarkers associated with its polymorphisms. In particular, these studies reported significant associations between SLC22A1 polymorphisms and drug disposition, response, and toxicity. SLC22A1 is abundantly expressed in the liver, and found on the sinusoidal membrane of hepatocytes. Polymorphisms in the transporter have been well characterized in in vitro uptake studies, and many polymorphisms lead to functional changes in protein expression and transport activity (Table S3) . Importantly, a number of clinical studies have been published describing significant associations between SLC22A1 polymorphisms and drug pharmacokinetics and pharmacodynamics effects ( Table S2) . Many of these associations have focused on the antidiabetic drug, metformin, and include metformin disposition, [8] [9] [10] [11] response, 12, 13 and adverse effects. 14, 15 However, studies of the effects of SLC22A1 polymorphisms on metformin pharmacokinetics and pharmacodynamics have been inconsistent. For example, while significant associations of nonsynonymous SLC22A1 polymorphisms with metformin plasma concentrations were observed in several pharmacogenomics studies, [8] [9] [10] [11] 16 other studies failed to observe such effects in either healthy subjects or patients with type 2 diabetes. [17] [18] [19] Recently, using 11 C-metformin positron emission tomography (PET) / computed tomography (CT), Sundelin et al. showed that individuals who are carriers of the OCT1 reduced function variants, Met420Del and Arg61Cys, have decreased concentrations of metformin in the liver without changes in systemic plasma levels compared with individuals with reference SLC22A1. 10 Together, these studies suggest that hepatic distribution of metformin is decreased in carriers of SLC22A1 reduced function variants and that plasma levels of metformin do not reflect hepatic exposure. These findings are in contrast to minor changes in the liver exposure and pharmacodynamics of statins in the case of SLCO1B1 polymorphisms. 20 Renal clearance is also a significant contributor to metformin elimination, unlike statins, where hepatic elimination is the predominant route. Therefore, metformin liver and plasma exposure will be affected by multiple mechanisms and consequences of reduced uptake into liver on systemic plasma levels would not be similar to statins 21 (also see Guo et al., Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and PBPK Modeling Approaches, this issue).
Associations between SLC22A1 polymorphisms and drug levels or response to prescription drugs other than metformin have been described (Table S2 ). These studies have demonstrated significant associations between reduced function nonsynonymous variants of SLC22A1 and the antimigraine drug, sumatriptan, 22 the opiate analgesic drugs or their metabolites, morphine, 4 and O-desmethyltramadol, 23 and the antinausea drug, ondansetron.
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In these studies, volunteers were classified based on the number of active SLC22A1 alleles that they harbor, e.g., zero, one, or two active alleles (Table S2) . Some studies identified significant correlations between systemic plasma levels of drug and genetic polymorphisms in SLC22A1. For example, exposure to fenoterol, a b 2 -adrenergic receptor agonist used in the treatment of asthma, was inversely correlated with the number of active SLC22A1 alleles, 24 i.e., higher levels of fenoterol were associated with zero active alleles of SLC22A1. In addition, drug exposure was correlated with effect; that is, individuals with less active SLC22A1 alleles and higher systemic concentrations had a greater increase in heart rate, an adverse effect of b 2 -adrenergic receptor agonists. 24 Studies with SLC22A1 polymorphisms have used a different study design than studies focused on polymorphisms of ABCG2 and SLCO1B1. In particular, reduced function polymorphisms are combined for SLC22A1 and the number of active alleles is associated with a pharmacologic trait, 4, 9, 23 whereas for SLCO1B1 and ABCG2, most studies have focused on associations between a single polymorphism and a pharmacologic trait.
Similar to ABCG2 and SLCO1B1, the studies of SLC22A1 polymorphisms have important implications for evaluation of potential DDI risk. For example, a perpetrator drug that inhibits OCT1 at clinically relevant concentrations may phenocopy the effect of the SLC22A1 reduced function polymorphisms. For example, an OCT1 inhibitor may increase fenoterol levels, resulting in increased heart rate effects of the drug. To our knowledge, to date no approved drugs have been found to inhibit OCT1 clinically (see Zamek-Gliszczynski et al. in this issue).
Collectively, review of the available data in the literature suggests that in addition to ABCG2 and SLCO1B1, polymorphisms in SLC22A1 be considered during drug development, particularly for drugs that are OCT1 substrates. We suggest that drug developers consider conducting pharmacogenomic studies for new drugs that are substrates of OCT1, especially for drugs that have narrow therapeutic indices. Further, we suggest that the nonsynonymous single nucleotide polymorphisms (SNPs) in SLC22A1, Arg61Cys, Cys88Arg, Gly401Ser, Met420del, and Gly465Arg are given the highest priorities and that the data analysis may consider individuals with 0, 1, or 2 of any of these nonsynonymous SNPs of SLC22A1, similar to published studies 4, 9, 23 ( Table S2 ). The allele frequencies in the ethnic population should be considered in the design of the study (see Table S3 for allele frequencies of nonsynonymous OCT1 SNPs in various ethnic groups). In some ethnic groups, allele frequencies of reduced function polymorphisms are very low, and, therefore, carriers of these alleles are uncommon, making pharmacogenomic studies exceedingly difficult. Pharmacogenomic studies need to focus on ethnic groups that have higher allele frequencies of reduced function polymorphisms of OCT1 such as individuals of European or Hispanic ancestry ( Table 2) .
POLYMORPHISMS IN OTHER DRUG TRANSPORTERS WITH LESS EVIDENCE
In addition to SLCO1B1, SLC22A1, and ABCG2, other important membrane drug transporters recommended by the US Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and European Medicines Agency (EMA) drug-drug interaction guidance/guidelines for study during drug development include SLC22A2 (OCT2),
, and ABCB1 (P-gp) (see Table 1 for the list of URLs to regulatory guidances and guidelines mentioned in this review). Below we briefly summarize candidate gene studies of these transporters. Table 2 gives an overview of the key polymorphisms highlighted below. For lists of publications about these polymorphisms, see the following publicly available resources: PharmGKB, ClinVar, Human Longevity Inc. Open Search, and others (see Figure 2 ).
Polymorphisms in SLC22A2 (OCT2)
OCT2 mediates the uptake of many drugs, including antidiabetic drugs, platinum anticancer drugs, and histamine H 2 receptor blockers, across the basolateral membrane of tubular epithelial cells. 25 In vitro studies of SLC22A2 genetic polymorphisms have been controversial. For example, some studies have shown that genetic variants of SLC22A2 result in a significantly reduced uptake of metformin, lamivudine, and other substrates, [26] [27] [28] [29] whereas other studies have failed to show effects of SLC22A2 polymorphisms on substrate uptake. 30, 31 Clinical data suggest that SLC22A2 variants are associated with metformin disposition and response, 30, [32] [33] [34] cisplatin toxicity, 35 as well as with levels of a variety of endogenous metabolites in humans. 36 However, here again, clinical studies have been inconclusive, as various studies report opposite associations between these genetic variants in SLC22A2 and clinical drug levels. 28, 30, 34 Polymorphisms in SLC22A6 (OAT1) and SLC22A8 (OAT3) OAT1 and OAT3 are renal transporters involved in the elimination and disposition of important drugs including statins, diuretics, nonsteroidal antiinflammatory drugs, and antimicrobial drugs (see UCSF-FDA Transportal, http://transportal.compbio. ucsf.edu/). Data indicate that the coding regions of SLC22A6 and SLC22A8 have low genetic and functional diversity and suggest that coding region variants of these transporters may not contribute substantially to interindividual differences in renal elimination of xenobiotics. [37] [38] [39] Despite clinical evidence from DDI studies, which demonstrate that inhibition of these transporters significantly changes the levels of many endogenous metabolites (e.g., taurine, creatinine, indoxyl sulfate, bile acid conjugates) [40] [41] [42] or victim drugs, 43, 44 there are few significant associations of genetic polymorphisms in SLC22A6 or SLC22A8 with drug levels or response. In fact, to our knowledge, only one study showed a significant association (P < 0.05) of an SLC22A8 Asian-specific nonsynonymous variant, Ile305Phe (rs11568482) with reduced renal and secretory clearance of the antibiotic, cefotaxime. 45 However, the effect of this variant has not been evaluated in an independent study.
Polymorphisms in SLC47A1 (MATE1) and SLC47A2 (MATE2)
MATE1 is expressed on the canalicular membrane of hepatocytes and on the apical membrane of the renal proximal tubule cell, where it serves to secrete drugs into the urine. 46 MATE2 is expressed specifically on the apical membrane of the proximal tubule and works in concert with MATE1 in renal drug Reduced transporter activity and some with reduced protein expressions on the membrane (see Supplemental Table S1 )
Increased plasma levels of drug, which could lead to increased drug toxicity ( Table 2) KO mice: Yes DDI: Yes GWAS: Yes (serum creatinine and metabolite levels)
Contradictory results in in vitro studies. Some groups showed reduced uptake, and some showed increased or no effect (see Supplemental   Table S1 )
Contradictory results in literature about the effect of the variant with metformin disposition
SLC22A6 and SLC22A8
No polymorphisms in these genes that are significantly associated with pharmacogenomic traits in multiple studies. secretion. 47 These transporters are known to transport many drugs, including metformin, oxaliplatin, and cimetidine (see UCSF-FDA Transportal). Although in clinical studies, MATE1/MATE2 inhibitors produced significant differences in endogenous metabolite levels 48 and in the disposition of MATE1/MATE2 substrates, 49, 50 evidence indicating that genetic polymorphisms in the transporters can phenocopy the effects of clinical MATE inhibitors is inconsistent. For example, an intronic variant in SLC47A1 (rs2289669), without known function, is associated with metformin response in several studies, 12, 18 but not in other studies. 17 Similarly, the functional variants in SLC47A1 (5 0 UTR, rs2252281) and SLC47A2 (5 0 UTR, rs12943590) also showed significant associations with metformin disposition and response in a small cohort of 200 patients with type 2 diabetes, 51,52 but were not associated with response to metformin in a large cohort of patients with type 2 diabetes. 17 Considering that changes in metformin pharmacokinetic and pharmacodynamics as a result of transporter modulation are complex, these findings would need to be confirmed with other drug probes. Recent studies have shown that there are ethnic differences in metformin response. In particular, patients from AfricanAmerican ancestry have a better response to metformin than patients from European ancestry. 53, 54 Further, the pharmacogenomic studies involving SLC47A1 or SLC47A2 have been carried out primarily in individuals of European ancestries. Thus, further studies are needed to determine the effects of polymorphisms in the MATEs on the disposition and response to metformin in other populations.
Polymorphisms in SLCO2B1 (OATP2B1)
OATP2B1 is expressed in all tissues (GTEx Portal), including the tissues of interest for xenobiotic absorption and disposition, such as brain (luminal membrane of endothelial cells of the blood-brain barrier), small intestine, and liver (basolateral/ sinusoidal membrane of hepatocytes). 1 Further, the transporter is expressed in many tumors, such as tumors originating in breast and prostate. 55 OATP2B1 mediates the transport of structurally diverse organic anions (sulfobromophthalein, methotrexate, pemetrexed, folic acid, reduced folates) (see UCSF-FDA Transportal). Emerging data suggest that SNPs within SLCO2B1 associate with altered protein function and clinical efficacy and/or safety. Several studies have evaluated the impact of an SLCO2B1 nonsynonymous SNP, rs12422149 (Arg312Gln), on drug response. The results show that OATP2B1-Arg312 is associated with increased transport of dehydroepiandrosterone (DHEAS) and increased resistance to androgen-deprivation therapy (ADT), 56 as well as lower overall survival rates in patients with prostate cancer. 56, 57 Another independent study showed that OATP2B1-Arg312 is significantly associated with shorter time to progression in prostate cancer patients treated with androgen deprivation. 58 Furthermore, the nonsynonymous polymorphism, OATP2B1-Gln312, was associated with poorer response to rosuvastatin. 59 However, the effect of this SLCO2B1 nonsynonymous variant was not significant in the disposition or response for other substrates, e.g., montelukast. 60, 61 Several clinical studies have shown that apple juice or grapefruit juice can inhibit OATP2B1, and hence reduce absorption (reduce plasma AUC levels by >1.5-fold) of several drugs that are substrates of The asterisk (*) shows that the database is not publicly available. See Table S4 for links to each of the databases, as well as for descriptions of the database categories.
OATP2B1, such as fexofenadine, atorvastatin, and celiprolol. 62, 63 More recently, a drug in early development, ronacaleret, unexpectedly reduced plasma levels of rosuvastatin, a substrate of OATP2B1, 64 by 50%. These interaction studies suggest that, similar to the inhibition effects of juice or drugs on OATP2B1 transport function, SLCO2B1 reduced function variants may play a role in modulating drug disposition (Table S3) .
OATP1B3 is predominantly expressed in hepatocytes (basolateral/sinusoidal membrane). 1 The transporter mediates the transmembrane flux of bile acids, cholesterol, hormones, and their metabolites, as well as drugs such as HMG-CoA reductase inhibitors, antihypertensive drugs, anticancer drugs, HIV protease inhibitors, and others (see UCSF-FDA Transportal). An assessment of polymorphisms (SNPs) in SLCO1B3 revealed that a number of variants were associated with anticancer drug and immunosuppressant drug response or toxicity (see https://www.pharmgkb.org/gene/PA35844/variantAnnotation). For example, patients who are carriers of the T allele of rs4149117 (OATP1B3-Ser112Ala, c.334T>G), were 19% less sensitive to thrombocytopenia from carboplatin/paclitaxel treatment than the homozygotes for the G allele.
65 SLCO1B3 699GG (rs7311358, OATP1B3-Met233Ile, c.699G>A) and 344TT (rs4149117) genotypes are also associated with nonresponse to imatinib in patients with chronic myeloid leukemia. 66 Collectively, studies suggest that OATP1B3 may be an important polymorphic transporter for new and approved drugs.
Polymorphisms in ABCB1 (P-gp, MDR1)
The multidrug resistance-1 (MDR1) protein belongs to the ATP-binding cassette (ABC) family and encodes the efflux pump, P-glycoprotein (P-gp). P-gp, expressed in tumors, mediates drug resistance to many anticancer drugs 67 and its roles in the intestine and blood-brain barrier have been extensively studied using different experimental methodologies such as knockout mice, 68 imaging probes, 69 and clinical studies of genetic polymorphisms. 70 The most highly studied polymorphisms in ABCB1 are the synonymous variant, C3435T (Ile1145Ile, rs1045642), and the nonsynonymous variant, G2677T, Ala893Ser (rs2032582). These common polymorphisms are found in all ethnic groups. Functional studies showed that the C3435T variant is associated with lower expression levels of P-gp in the duodenum 71 and placenta 72 and that these lower expression levels have been correlated with increased digoxin plasma concentrations. 71 The ABCB1 nonsynonymous variant, Ala893Ser, has been shown to cause reduced function and increased accumulation of substrates inside cells. 73, 74 However, controversial and conflicting data of these polymorphisms were reviewed previously 75, 76 (also see resources: https://www.pharmgkb.org/search?connections&gaSearch=rs2032582&query=rs2032582 and https:// www.pharmgkb.org/search?connections&gaSearch=rs1045642&quer y=rs1045642).
Polymorphisms in ABCC2 (MRP2)
The multidrug resistance-associated protein-2 (MRP2) belongs to the ABC family. This transporter is highly expressed in the liver and kidney, and serves to efflux drugs from the cells into the bile and urine, respectively. Rare mutations in ABCC2 are known to cause a Mendelian disorder, Dubin-Johnson syndrome, which causes conjugated hyperbilirubinemia (https://www.omim.org/ entry/601107). Many drugs and glucuronide-conjugated drug metabolites are known substrates of MRP2, e.g., methotrexate, the irinotecan inactive metabolite, SN-38 glucuronide, and etoposide (see UCSF-FDA Transportal). The most highly studied polymorphism in ABCC2 is the promoter variant, c.-24C>T (rs717620). This promoter variant is associated with lower expression levels of ABCC2 77 ( Table S3) . Several candidate gene studies have identified significant associations of the variant with drug levels, 78, 79 toxicity, 80, 81 and response 82 of anticancer drugs, such as methotrexate and irinotecan. The effect of this variant on drug response shows contradictory results, which may be due to small sample sizes or differences in the populations studied (see PharmGKB for clinical studies which are significant or not significantly associated with this promoter variant).
In summary, although there is some evidence that SNPs in the transporters in this section contribute to variation in drug response and toxicity, more experiments are clearly needed. For SNPs in SLC22A2 (OCT2), SLCO2B1 (OATP2B1), SLC47A1 (MATE1), ABCB1 (P-gp), and ABCC2 (MRP2), reports in the literature have been conflicting, and sample sizes have generally been small. For variants of SLCO1B3 (OATP1B3) and SLC22A6 (OAT1), only a few studies have been published. Clarification with further studies and studies of larger sample sizes will greatly enhance our understanding of the clinical implications of polymorphisms in these transporters.
FUNCTIONAL GENOMICS OF DRUG TRANSPORTERS
From a mechanistic view, polymorphisms in membrane transporter genes can modulate transport function by affecting either the activity of the transporter or expression level of the transporter protein. Polymorphisms can affect transporter activity through several mechanisms. For example, polymorphisms in the binding site of the transporter may directly affect the binding and debinding of substrates and may act in a substrate-dependent fashion (e.g., SLC47A2 missense variant, Gly393Arg). 51 In contrast, missense variants not found in the binding site may affect the expression level of the transporter protein in the plasma membrane by altering trafficking to and from the plasma membrane or protein stability (e.g., SLC47A2 missense variant, Pro162Leu). 51 Noncoding region variants as well as synonymous variants (and some nonsynonymous variants) may affect the mRNA expression level of the transporter by affecting rates of transcription or RNA stability. In this section, we provide a list of functionally characterized coding and promoter variants of 12 major transporters that play a role in drug absorption, disposition, and toxicity, along with their in vitro effects on protein function or expression ( Table S3 ). The majority of the SNPs were discovered in large sequencing projects of multiple genes, and a large research project focused on membrane transporter polymorphisms, the Pharmacogenomics of Membrane Transporters project. 83 More recently, genetic polymorphisms across the genome have been discovered through multiple sequencing efforts, and frequently accessed databases now post genetic variants in all genes: Exome Variant Server and eMERGE SPHINX (see more examples in Figure 2 and Table S4 ). Below, we highlight key examples in which the genetic polymorphism leads to functional changes.
Transporter variants that cause changes to transporter activity or protein expression Nonsynonymous transporter variants have been characterized using site-directed mutagenesis in mammalian cells (e.g., HEK293, CHO, HeLa) or X. laevis oocytes (see references in Table S3 ). For transporter variants that retain some functional activity, kinetic studies have been performed to determine the Michaelis-Menten constants (K m and V max values) of the variant transporters for various substrates. For some transporters, further studies to determine the molecular mechanisms responsible for changes in kinetic parameters have been performed, including structural modeling, in situ docking of substrates in the binding pocket of the variant transporter, and measurement of the transporter protein level on the cell membrane. A glance at Table S3 shows 180 nonsynonymous variants that have been characterized in cellular assays, of which 50% exhibited reduced transporter function and/or expression levels on the membrane compared to the reference allele. Many of these reduced function variants are substratedependent. Generalizable findings for functional studies of drug transporter variants are as follows:
Several well-characterized xenobiotic transporters have common reduced function nonsynonymous variants found at allele frequencies greater than 10% in particular ethnic populations. These include: OATP1B1-V174A (rs4149056), BCRP-Q141K (rs2231142), and OCT1-420del (rs202220802). These variants have been associated with changes in efficacy and safety for a number of drugs and are considered in this article as highly significant transporter polymorphisms (see Tables S1, S2) . Mechanisms responsible for reduced function are more frequently related to reduced protein expression levels on the cell surface membrane (e.g., OATP1B1-V174A and BCRP-Q141K) rather than direct effects on substrate binding and translocation. Less common and rare nonsynonymous variants (minor allele frequency (MAF) <1%) are more likely to exhibit significant reductions in their uptake kinetics than more common variants. Most of the 12 transporters have at least one less common nonsynonymous variant (1-5% in at least one population) that affects transporter kinetic parameters and many of these are present in one ethnic group only. Examples are: OCT1-G401S (European), OCT2-K432Q (African), MATE2-P162L (African), OAT1-R50H (African), OAT3-I305F (Asian), and OATP1B1-G488A (African).
The majority of less common reduced-function transporter variants have not been associated with drug disposition or response in clinical studies, presumably due to their low allele frequencies and the difficulty of obtaining sufficient numbers of study subjects who harbor the variants.
Collectively, these findings suggest that further studies should be conducted assessing the associations of less common and rare variants in transporters and drug response, or combinations of less common and rare variants in individual transporters (as in the case of OCT1).
Transporter variants that cause changes in transcriptional rates
Although many noncoding variants in transporter genes are associated with variation in drug response (Table S3) , few of these variants have been characterized. A handful of variants in promoter, enhancer, or UTR regions of these transporters have been functionally characterized using reporter assays with luminescent probes such as luciferin (19742321) . In general, the effect of variants in noncoding regions may be subtle modulating, but not ablating, expression levels. A noncoding region variant in a transporter gene may change the expression level of the mRNA transcript and, correspondingly, the transporter protein level. Variants that are associated with changes in transcript levels are termed expression quantitative trait loci (eQTL). Through major efforts of consortia or large research projects, many eQTL databases are available publicly. These databases allow users to look up genetic polymorphisms in any gene, including membrane transporter genes, and determine whether they are significantly associated with mRNA expression levels of the transporter or other genes in various tissues. The most popular eQTL database is the GTEx Portal. In Table S3 , we highlighted several SNPs in the promoter and UTR regions of transporters that are known eQTLs and alter luciferase activity in reporter assays.
CLINICAL STUDY DESIGN AND THE USE OF MODELING AND SIMULATION Clinical study design
Studies of the clinical effects of transporter polymorphisms can provide enormous insights into the role of a transporter in drug disposition, response, and toxicity. Unlike DDI studies, which often involve the use of nonselective inhibitors, studies of transporter polymorphisms provide direct evidence for the pharmacologic role of a particular transporter. However, such studies may be challenging due to the low allele frequencies of many transporter polymorphisms (<20%), and the fact that the effects of transporter polymorphisms are largely seen in individuals who are homozygous. Thus, Hardy-Weinberg equilibrium predicts that for a variant with an allele frequency of 20%, only 4% of the population will be homozygous. Of course, if allele frequencies are lower, homozygotes will be even rarer; leading to underpowered studies or studies where conclusions are drawn from a handful of patients. Other issues that should be addressed during drug development are when and how to evaluate the effects of genetic polymorphisms on drug disposition or response. As in our previous article, 2 we recommend that during all phases of drug development, genetic polymorphisms in drug transporters are studied. Furthermore, recent guidances from regulatory groups (e.g., the FDA draft guidance of Clinical Drug Interaction Studies, the FDA guidance of Clinical Pharmacogenomics, the International Council for Harmonization (ICH) Guideline E18 on Genomic Sampling and Management of Genomic Data, and the FDA final guidance of E18 Genomic Sampling and Management of Genomic Data (see URLs in Table 1 )) encourage sponsors to routinely collect DNA from all subjects for retrospective analysis of polymorphisms in transporters of interest. In the preclinical phases of drug development, it is important to characterize which transporters are important determinants of the drug disposition. For substrates of BCRP or OATP1B1 in which the transporter plays an important role in drug disposition, the ITC recommends that clinical studies are considered to assess the effects of genetic variants on the pharmacokinetics and if possible pharmacodynamics. 84 Key considerations for pharmacogenomic clinical designs have been reviewed. 85 
Pharmacogenomic discovery studies
Although there have been a number of candidate gene pharmacogenomics studies focused on transporter polymorphisms, many have been underpowered to make meaningful conclusions. Further, most have focused on more common variants in transporter genes. To enhance reproducibility of results and explore the effects of less common genetic variants, larger sample sizes are needed. In order to accomplish this feat, many investigators are pooling samples to obtain the necessary sample sizes. For example, a recent meta-analysis examining the association between genetic variants in transporter genes and metformin response included up to 7,968 samples. 17 In addition to underpowered studies focused on candidate genes, most of the retrospective pharmacogenomic studies have evaluated the effect of transporter variants in isolation, i.e., lack the information on the potential effect of multiple coexisting genetic covariates (e.g., SLCO1B1 and ABCG2 polymorphisms in the same subject) together with demographic factors (e.g., age, ethnicity) on the pharmacokinetics of a drug and/or its DDI sensitivity. The population pharmacokinetic modeling reported recently for simvastatin acid identified a combination of genetic and demographic risk factors associated with altered simvastatin exposure and increased myopathy risk that was not solely attributed to rs4149056. 86 In addition, a number of studies have reported differences in transporter activity and plasma exposures of statins between Japanese and Caucasian populations, which appear to extend beyond the SLCO1B1 genotype. 86, 87 However, these findings have been challenged in other studies, which suggest that genetic variants in SLCO1B1 and ABCG2 may explain much of the ethnic differences between plasma exposures of statins. 88 
Role of modeling and simulation
Modeling and simulation, especially physiologically based pharmacokinetic (PBPK) models, can be used to understand and project the effects of genetic polymorphisms on pharmacokinetics and pharmacodynamics during drug development, as illustrated in a number of literature examples predominantly focusing on OATP1B1. 21, 89 Recently, a PBPK modeling approach was applied to predict morphine clearance and associated intersubject variability in children with different OCT1 allelic variants. 90 Plasma concentrations of many prescription drugs are affected by SLCO1B1 polymorphisms, particularly the OATP1B1-Val174Ala variant (rs4149056, c.521T>C). 2 In spite of their strong associations with systemic plasma levels and muscle toxicities of various statins, SLCO1B1 polymorphisms have minimal effect on the pharmacodynamics of statins, i.e., their lipidlowering effects. 20, 91 These observations can be explained by understanding that hepatic elimination is the predominant route and that metabolic clearance (simvastatin acid) and biliary efflux (pravastatin) rather than active uptake determine liver exposure of statins. 21, 92, 93 In contrast, polymorphisms in efflux transporters on the canalicular membrane such as BCRP (or efflux transporter-mediated DDI) are expected to have a significant effect on liver exposure. 84 Verification of these model-derived tissue exposures and associated challenges are discussed in detail in the Guo et al. white paper in this issue. A PBPK model-based approach also provides a framework to inform power calculations and guide the design of either pharmacogenetic or DDI studies, as illustrated by Gertz et al., 89 where this mechanistic approach was applied to simulate repaglinide exposure in subjects with coexisting CYP2C8*3 and OATP1B1-Val174Ala.
Pharmacogenomic clinical data provide an incredibly valuable dataset for the verification of the PBPK models, as they allow evaluation of the importance of individual transporters/ elimination mechanisms in the model. Recent examples illustrate the use of plasma data from different SLCO1B1 variant groups to validate PBPK models developed for repaglinide, simvastatin acid, simeprevir, and pitavastatin. 21, 89, 94 Following initial verification of the simulated plasma profiles against pharmacogenomic data, PBPK models were subsequently used to predict liver and muscle exposure in subjects with different polymorphism and/or predict DDIs with these clinical probes. Overall, there is less confidence in transporter PBPK models compared to PBPK models for drug-metabolizing enzymes because of knowledge gaps in transporter biology and limited experience in determining and modeling the kinetics of transporters (see this issue by Guo Y. et al.). The recently revised FDA draft guidance of In Vitro Metabolism and Transporter-Mediated Drug-Drug Interaction Studies (see Table 1 ) recommends that clinical data from a wide range of DDI or pharmacogenetic studies be used to verify PBPK models developed for transporter substrates.
FUTURE DIRECTIONS AND CONCLUSIONS
Future directions will depend on continued use and growth of technology in the discovery of important associations between genetic variants in transporters and drug response, as highlighted below.
Genomewide association studies GWAS continue to be a powerful tool for determining the role of transporters in human biology and pharmacology. In fact, in addition to genomewide-level, significant results between pharmacogenomics traits and polymorphisms in ABCG2 and SLCO1B1, GWAS have revealed associations between polymorphisms in other ABC and SLC transporters and drug response at genomewide level significance (P < 5310 -8 ) (Tables S1, S5) . 95 Surveying the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/) and PubMed, we identified 11 publications relevant to pharmacogenomic traits, which described significant associations with polymorphisms in ABC or SLC transporter genes or loci (P < 5310 -8 ). However, with the exception of polymorphisms in ABCG2 and SLCO1B1, associations between polymorphisms in other transporter genes (e.g., SLC17A1, SLC2A2, SLC15A1, SLCO1B3) ( Table S5 ) and pharmacogenomic traits have yet to be replicated in independent cohorts. It is envisioned that some of these associations will be replicated in future studies. GWAS is envisaged to facilitate identification of potential endogenous biomarkers for transporters, as reported recently for OATP1B1, 96 especially considering interest in application of endogenous biomarkers to support evaluation of transporter-mediated DDI risk in the early stages of drug development (see Chu et al. in this issue for details). In the last few years, there has been growing interest with phenome-wide association studies (PheWAS), in which many phenotypes (disease, traits, drug response, etc.) are correlated with a particular single genetic polymorphism. 97 For example, scanning across all the available GWAS, one could look for new implications of a single polymorphism, such as those in transporters. Such resources are publicly available, e.g., Phe-WAS Resources, https://phewascatalog.org/.
Massively parallel sequencing
In recent years, massively parallel sequencing has been increasingly used for discovering SNPs in pharmacogenes in large and diverse ethnic populations from various regions of the world. [98] [99] [100] The majority of these studies have focused on CYP enzymes. However, some of these studies have included membrane transporter genes known to play a role in drug response, such as SLCO1B1 and ABCG2. 98, 99 Leveraging publicly available human variation databases, such as the 1000 Genomes Project, Exome Variant Server, and gnomAD browser (see Figure 2 , Table S4 ), allows an extensive examination of the spectrum of genomic variations across all genes, including SLC and ABC transporters. Some advantages of nextgeneration sequencing (NGS) methods are that they are potentially cheaper and analyses are simpler compared to traditional Sanger sequencing. Further, the results generated from NGS allow reanalysis of the raw sequencing data, especially when updated information about new variants or reclassified variants become available in the future. Although NGS has been used for discovering SNPs, its use in the identification of the genetic determinants of drug response and adverse drug response has been very limited. The following are examples of how NGS have been used in the discovery of variants in membrane transporters, which are associated with drug disposition, response or toxicity.
NGS to identify genetic determinants for drug levels (or exposure). Recently, the Niemi laboratory used NGS to sequence candidate genes to identify the genetic basis of interindividual variation in response to montelukast and clopidogrel as well as concentrations of drug metabolites. 101, 102 These studies were conducted in 190 healthy volunteers, focusing on relevant enzymes and membrane transport proteins. The results showed that individuals who are carriers of uridine diphosphateglucuronosyltransferase (UGT), UGT1A3*2 (rs3821242 and rs6431625) have lower montelukast exposure and greater exposure to montelukast metabolites with very large effect sizes (effect size 18% change per copy of minor allele, P < 10 -9 ). In general, these SNPs are not readily available in genotyping arrays (see NCBI dbSNP) and thus massive parallel sequencing facilitated the discovery of common SNPs (40% allele frequencies) associated with montelukast exposure. Other candidate genes, including the transporters, ABCC9 and SLCO1B1 were also associated with montelukast metabolite concentrations. NGS to identify genetic determinants for nonresponse to medication. NGS technology was also used to sequence DNA from patients who are extremely resistant to particular medications. For example, Chua et al. 103 performed whole-exome sequencing of DNA samples from 12 patients who exhibited extreme therapeutic resistance to azathioprine or 6-mercaptopurine. The study was designed to focus on genes within the drug disposition pathway, which included SLC and ABC transporters as well as enzymes. 103 Although the sample size was small, a potential missense variant in the transporter SLC17A4 had significantly higher allele frequency in the patients (3/24 (12.5%)) compared to population controls from public data sources (101/8,600 (1.2%)) (P < 0.0001).
In addition to its use in the discovery of variants that associate with clinical drug response, disposition, and toxicity, NGS technology is also being used in preemptive genotyping in the patient care setting. The design and implementation of preemptive approaches to integrate pharmacogenomic data in the electronic health record has begun in several healthcare institutions since 2012 and may include functional variants in SLCO1B1 and ABCG2 (see examples) 104, 105 . Although genotyping using arrays is most commonly employed in preemptive studies, there are recent examples where exome-sequencing with NGS has slowly been adopted in a few healthcare institutions, such as the eMERGE-PGx Project. 106 In these studies, genotype information is deposited in the electronic health record along with some decision support tools, with the goal of assisting clinicians in the use of genomic information to guide choice of therapies and doses.
Drug development perspective
Pharmaceutical industry-leading practices now incorporate pharmacogenomics routinely in drug development to better understand drug safety and response in individual patients. For many years, pharmacogenomic studies largely focused on common polymorphisms in drug-metabolizing enzymes. However, proactive strategies now include genotyping patients using genome-wide platforms that are specifically enriched for ADME genes including transporters. With this approach, data are collected during the conduct of the trial (and across many trials in a drug development program) and can be retrospectively analyzed for association with disposition, toxicity, and/or efficacy. Costs of collection, genotyping, and long-term biorepository storage are now in the realm of making this a relatively low-cost endeavor. 107, 108 Furthermore, as more companies adopt such strategies, logistics are enabled by several commercial organizations offering such services. Such practice has resulted in a relatively low-cost approach to improved understanding of pharmacokinetic and pharmacodynamic mechanisms, including the role of particular transporters and enzymes in the absorption, disposition, efficacy, and toxicity of drugs. While it is not uncommon to identify genetic polymorphisms that are statistically associated with differences in drug disposition, it is also not uncommon that those differences are deemed clinically nonmeaningful when considering the therapeutic window of the drug. When clinically meaningful associations exist, it is important to identify those during drug development and understand their effect with respect to other coexisting polymorphisms so that appropriate dosing or exclusion decisions can be made. In addition to improved practices with the industry and better understanding of the pharmacologic mechanism, regulators are increasingly expecting and asking for such data.
CONCLUSION
In this review, evidence has been presented that genetic polymorphisms in the emerging transporter, SLC22A1, be considered in addition to previously recommended polymorphisms in ABCG2 and SLCO1B1 during drug development when evaluating mechanisms responsible for interindividual variation in drug disposition, response, and toxicity. Review of clinical and functional genomic studies of other drug transporters including SLCO2B1, SLCO1B3, ABCB1, and ABCC2 suggests that further studies are needed to understand the role of polymorphisms in these transporters in clinical drug disposition and response. The integrated use of PBPK modeling and pharmacogenomic data to support model development and improve our understanding of the consequences of genetic variants in membrane transporters on drug disposition and response is recommended. Future studies using GWAS and massively parallel sequencing approaches in larger cohorts of patients are clearly needed to advance our understanding of transporter polymorphisms and variation in drug disposition and response so that they may be fully integrated into clinicians' decision-making when choosing doses and therapies.
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